Immunotherapeutic perspective for bispecific antibodies.
Bispecific antibodies (BsAb) can, by virtue of combining two binding specificities, improve the selectivity and efficacy of antibody-based treatment of human disease. Recent studies underline the importance of both the 'anti-trigger' and 'anti-target' modalities of BsAb for therapeutic efficacy. Several BsAb induce effective cytotoxicity as well as 'vaccine effects' in vivo. Here, Annemiek van Spriel and colleagues discuss how these results have catalysed renewed efforts to translate BsAb concepts into effective therapies.
Immunotherapy Laboratory, Dept of Immunology and Medarex Europe, University Medical Center Utrecht, Room KC02.085.2, Lundlaan 6, 3584 EA Utrecht, The Netherlands.
A B
AB
van Spriel
H H
HH
van Ojik
J G
JG
van De Winkel
D000818:Animals; D018033:Antibodies, Bispecific / Q000276:immunology* / Q000627:therapeutic use*; D002176:Candida albicans / Q000276:immunology; D002986:Clinical Trials as Topic; D006801:Humans; D008214:Lymphocytes / Q000276:immunology; D016393:Lymphoma, B-Cell / Q000628:therapy; D051379:Mice; D008822:Mice, Transgenic; D009504:Neutrophils / Q000276:immunology / Q000382:microbiology; D010587:Phagocytosis; D017452:Receptors, IgG / Q000172:deficiency / Q000235:genetics / Q000276:immunology
D018033:Antibodies, Bispecific; D017452:Receptors, IgG